Press Release | January 13, 2020 | Source: Oncologie Oncologie receives exclusive global license to develop and commercialize navicixizumab London, Redwood City, Calif., and Boston, January 13, 2020 – Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” and Oncologie, Inc. (“Oncologie”) today announced......
Press Release | October 09, 2019 | Source: Oncologie – The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population – Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and......
Press Release | August 12, 2019 | Source: Oncologie WALTHAM, Mass., Aug. 12, 2019 — Oncologie, Inc., a clinical-stage biopharmaceutical company developing innovative oncology treatments targeting the tumor microenvironment, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the......
Press Release | June 10, 2019 | Source: Oncologie BOSTON, June 10, 2019 — Oncologie, an innovative biopharmaceutical company using proprietary biomarkers to drive clinical development of next-generation oncology therapeutics, announced today that it has closed an $80M Series B financing. Existing investors, led by Nan Fung Life......
Press Release | August 03, 2018 | Source: HTG Molecular Diagnostics, Inc. TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with......
News Article | June 07, 2018 | Source: Oncologie, Inc. BOSTON and SHANGHAI, June 7, 2018 /PRNewswire/ — Oncologie, an innovative biopharmaceutical company, announced today that it is launching operations in both Boston and Shanghai with $16.5M seed financing led by Pivotal bioVenture Partners China. Oncologie is......
Press Release | February 13, 2018 | Source: Mologen BERLIN–(BUSINESS WIRE)–The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a license deal for the Chinese territory and a global co-development agreement between MOLOGEN and ONCOLOGIE Inc. for......
Press Release | February 12, 2018 | Source: Avid Bioservices, Inc. TUSTIN, Calif. and BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for......